NN9541 / Novo Nordisk - LARVOL DELTA

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=465 | Recruiting | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • CST3 • EGFR

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=134 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=465 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • CST3 • EGFR

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes (clinicaltrials.gov) - P1 | N=82 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (clinicaltrials.gov) - P1 | N=47 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Long-acting Reversible Contraceptives • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=299 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes (clinicaltrials.gov) - P1 | N=64 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Trial primary completion date: May 2025 ➔ Dec 2025

Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Novo Nordisk A/S | Trial primary completion date: Apr 2025 ➔ Jan 2026

Trial primary completion date • Genetic Disorders • Obesity

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Phase 2 trial completed with a once-weekly GLP-1/GIP co-agonist and development terminated in weight management (GlobeNewswire) - P2 | N=355 | NCT06326060 | Sponsor: Novo Nordisk A/S | "In June 2025, Novo Nordisk completed a phase 2 study with a once-weekly GIP/GLP-1 co-agonist analogue (NNC0519-0130) in people with overweight or obesity. The study investigated the safety and efficacy of different doses of NNC0519-0130. The primary objective was met, demonstrating statistically significantly greater body weight reductions compared with placebo across all doses investigated after 36 weeks of treatment. The safety profile of NNC0519-0130 was consistent with incretin-based therapies. Due to portfolio considerations, Novo Nordisk will not pursue further development of the GIP/GLP-1 co-agonist in weight management."

Discontinued • P2 data • Obesity

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight (clinicaltrials.gov) - P2 | N=355 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight (clinicaltrials.gov) - P2 | N=355 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Trial primary completion date: Nov 2024 ➔ Apr 2025

Trial primary completion date • Genetic Disorders • Obesity

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Novo Nordisk A/S | Trial completion date: Apr 2025 ➔ Nov 2024 | Trial primary completion date: Apr 2025 ➔ Nov 2024 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Jun 2025 ➔ Oct 2025 | Trial primary completion date: Feb 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Diabetes • Long-acting Reversible Contraceptives • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=465 | Recruiting | Sponsor: Novo Nordisk A/S | Trial primary completion date: Aug 2025 ➔ Sep 2026

Trial primary completion date • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes (clinicaltrials.gov) - P1 | N=64 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=465 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Long-acting Reversible Contraceptives

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=288 | Recruiting | Sponsor: Novo Nordisk A/S | Trial primary completion date: Nov 2024 ➔ Sep 2025

Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=465 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P2 trial • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus